Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

(2020) Nadia Howlader et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

(2020) Wen-Zhao Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations

(2019) Wenjie Tang et al.   LUNG CANCER

A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer

(2019) Hua Cheng et al.   LUNG CANCER

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

(2018) Wen-Zhao Zhong et al.   LANCET ONCOLOGY

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

(2018) Dongsheng Yue et al.   Lancet Respiratory Medicine

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

(2018) Song-Tao Xu et al.   Journal of Thoracic Oncology

Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients

(2017) T Wang et al.   INDIAN JOURNAL OF CANCER

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study

(2017) Baohui Han et al.   LUNG CANCER

Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients

(2017) T Wang et al.   INDIAN JOURNAL OF CANCER

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)

(2016) Michael Kreuter et al.   Journal of Thoracic Oncology

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations

(2016) Shuyang Yao et al.   Thoracic Cancer

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

(2015) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study

(2015) Xingsheng Hu et al.   PLoS One

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)

(2014) Xingsheng Hu et al.   LUNG CANCER

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

(2013) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

(2013) Yuankai Shi et al.   LANCET ONCOLOGY

A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma

(2013) Chao Lv et al.   World Journal of Surgical Oncology

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study

(2012) M. Kreuter et al.   ANNALS OF ONCOLOGY

Adjuvant chemotherapy for surgically resected non–small cell lung cancer

(2012) Stephanie Heon et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation

(2010) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

(2010)   LANCET

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

(2010) Qiong Zhao et al.   LUNG CANCER

Staging of non-small cell lung cancer (NSCLC): A review

(2010) S. Tsim et al.   RESPIRATORY MEDICINE